Several countries in the world are experiencing high rates of multi-drug resistant pathogens, particularly in hospitals leading to serious hospital-associated infections often requiring long hospital stay and increased treatment. The scenario is further complicated by reports of rise in community-onset multi-drug resistant infections and in the absence of an effective out-patient therapy; currently such patients too require hospitalization, thus further burdening the already overloaded hospital infrastructure. This situation highlights the need for MDR-active effective outpatient parenteral antimicrobial therapies (OPAT). OPAT has the potential to be the ‘standard-of-care’ to enable community management of resistant infections currently requiring hospitalizations. Odrate (zidebactam/ertapenem 2 g/2 g IV, once-daily) is being developed to address this unmet need of an OPAT drug with potential to treat the toughest resistant pathogens. Preclinical translational studies have shown that once-daily IV treatment with Odrate is bactericidal to nearly all variants of carbapenem-resistant Enterobacterales (E. coli, Klebsiella, Enterobacter etc) which are often the cause of community as well as hospital infections such as urinary tract and gastro-intestinal infections (UTIs). Recently, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), United States of America (USA) has successfully completed Phase 1 clinical trial in US for Wockhardt’s novel once-a-day, multidrug-resistant (MDR) Gram-negative targeted antibiotic Odrate. Once-a-day therapeutic profile of Odrate is expected to cut hospital admissions, facilitate early patient discharge and thus introduce patient-centric care for MDR infections. The Food and Drug Administration (USA) has granted a qualified infectious disease product (QIDP) designation to Odrate, which signifies its ability to meet unmet medical need and facilitates faster approval process.